knowledge -WSS

knowledge

author：entertainment 2025-09-30 19:26:01 - browse：4264

Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： The Bio Revolution is changing business and society

hotspot

WSS

Why palliative psychiatry is worth discussing

Should insurance cover cosmetic surgery?

Pharma’s losing bet in New Jersey

STAT readers on older presidents, polypills, Medicare, and more

Alabama hospital puts IVF treatments on hold

Stroke rates rising, especially in working

leisure time

knowledge

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Achieving telehealth equity for people with hearing loss

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.S. death rates show how politics are affecting public health

Medicare details structure of new drug price negotiation program

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Trump demands the U.S. pay no more for drugs than other countries … again

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Wildfire smoke exposes gaps in outdoor worker protections

Some medical students still think black patients feel less pain

leisure time

Alabama hospital puts IVF treatments on hold

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

U.S. death rates show how politics are affecting public health

A new nitrogen execution bill also undermines medical licensing

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Asahi Kasei to buy Calliditas, picking up kidney disease drug

knowledge

hotspot

focus

leisure time